Try Alerts Free   |   Login
Health Care › Surgical And Medical Instruments And Apparatus

NVRO Price Correlated With Financials For Nevro

Free historical financial statements for Nevro Corp. See how revenue, income, cash flow, and balance sheet financials have changed over 31 quarters since 2015. Compare with NVRO stock chart to see long term trends.

NVRO Stock Compared to Quarterly

NVRO Income Statement

Revenue, Net:100466000
Revenue Per Share:2.8356
Cost of Goods & Services Sold:31164000
Gross Profit:69302000
Selling, General & Admin Expense:78190000
Research & Development Expense:14030000
Total Operating Expenses:-12780000
Operating Income:82082000
Income Taxes:485000
Net Income:81508000
Earnings Per Share, Basic:2.3
Shares Outstanding, Basic Avg:35430089

NVRO Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:1602000
Change in Accounts Receiveable:3368000
Net Cash from Operations:79350000
Net Cash from Operations Per Share:2.2396
Net Cash from Financing Activities:37000
Property, Plant & Equipment Purchases:2113000
Net Cash from Investing Activities:-56504000
Net Change in Cash & Equivalents:21829000

NVRO Balance Sheet

Cash and Cash Equivalents:131445000
Accounts Receivable, Net:69572000
Inventories:98525000
Total Current Assets:566073000
Property, Plant & Equipment, Net:21173000
Total Assets:605512000
Accounts Payable:31839000
Total Short-Term Liabilities:80298000
Long Term Debt, Non-Current Portion:186559000
Total Liabilities:280577000

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock Inc.
4,871,522 sh
29,906 sh
1%
$227,012
$14,805
FMR LLC
4,354,248 sh
3,231,986 sh
288%
$202,908
$153,719
Vanguard Group Inc
3,621,085 sh
60,289 sh
2%
$168,743
$12,673
JPMorgan Chase & Co
1,598,269 sh
221,158 sh
16%
$74,480
$14,122
Arrowmark Colorado Holdings LLC
1,151,060 sh
-10,953 sh
-1%
$53,639
$2,708
Invesco Ltd.
1,044,181 sh
1,227 sh
0%
$48,659
$2,946
Fred Alger Management, LLC
933,195 sh
-303,094 sh
-25%
$43,487
-$10,699
Federated Hermes, Inc.
832,930 sh
-248,871 sh
-23%
$38,815
-$8,600
State Street Corp
821,509 sh
10,654 sh
1%
$38,282
$2,742
Principal Financial Group Inc
793,340 sh
136,107 sh
21%
$36,970
$8,164
Rock Springs Capital Management Lp
787,000 sh
13,700 sh
2%
$36,674
$2,780
Brown Advisory Inc
643,845 sh
6,447 sh
1%
$30,004
$2,067
Geode Capital Management, LLC
605,391 sh
14,417 sh
2%
$28,211
$2,309
Partner Fund Management, L.P.
563,560 sh
-95,850 sh
-15%
$26,262
-$2,640
Balyasny Asset Management LLC
541,043 sh
4,951 sh
1%
$25,213
$1,716
Credit Suisse Ag/
519,992 sh
-5 sh
0%
$24,231
$1,440
Wellington Management Group Llp
452,438 sh
-234,488 sh
-34%
$21,084
-$9,023
Morgan Stanley
432,071 sh
-67,696 sh
-14%
$20,135
-$1,771
Two Sigma Advisers, Lp
369,800 sh
51,000 sh
16%
$17,233
$3,260
Two Sigma Investments, Lp
344,577 sh
105 sh
0%
$16,057
$959
COMPANY PROFILE
1. Formation and Business of the Company
The Company was incorporated in Minnesota on March 10, 2006 to manufacture and market innovative active implantable medical devices for the treatment of neurological disorders initially focusing on the treatment of chronic pain. Subsequently, the Company was reincorporated in Delaware on October 4, 2006 and relocated to California.
Since inception, the Company has incurred net losses. During the year ended December 31, 2021, the Company incurred a net loss of $131.4 million and had $41.9 million of cash used in operations. At December 31, 2021, the Company had an accumulated deficit of $624.2 million. The Company has financed operations to date primarily through private placements of equity securities, borrowings under a debt agreement, the issuance of common stock in its November 2014 initial public offering, its June 2015 underwritten public offering and its June 2016 underwritten public offering of convertible senior notes due in 2021 (2021 Notes). Additionally, in April 2020, the Company issued a total of $189.8 million aggregate principal amount of convertible senior notes due 2025 (2025 Notes).  The total net proceeds from this debt offering, after deducting initial purchase discounts and debt issuance costs, were approximately $183.6 million. Concurrent with this debt offering, the Company also completed an underwritten public offering for 1,868,750 shares of its common stock, from which the Company received cash proceeds of $147.1 million, net of underwriting discounts and commissions and offering costs. The Company’s ability to continue to meet its obligations and to achieve its business objectives for the foreseeable future is dependent upon, amongst other things, generating sufficient revenues and its ability to continue to control expenses to meet its obligations as they become due. Failure to increase sales of its products, manage discretionary expenditures or raise additional financing, if required, may adversely impact the Company’s ability to achieve its intended business objectives.
Public Offerings
In June 2016, the Company issued $150.0 million aggregate principal amount of 1.75% convertible senior notes due 2021 in a registered underwritten public offering and an additional $22.5 million aggregate principal amount of such notes pursuant to the exercise in full of the over-allotment options of the underwriters (the 2021 Notes). The interest rates are fixed at 1.75% per annum and are payable semi-annually in arrears on June 1 and December 1 of each year, commencing on December 1, 2016.  The total net proceeds from the debt offering, after deducting transaction costs, were approximately $166.2 million.
In April 2020, the Company issued $165.0 million aggregate principal amount of 2.75% convertible senior notes due 2025 in a registered underwritten public offering and an additional $24.8 million aggregate principal amount of such notes pursuant to the exercise in full of the over-allotment options of the underwriters (the 2025 Notes).  The interest rates are fixed at 2.75% per annum and are payable semi-annually in arrears on April 1 and October 1 of each year, commencing on October 1, 2020.  The total net proceeds from the debt offering, after deducting transaction costs, were approximately $183.6 million.
Concurrent with the 2025 Notes, the Company completed an underwritten public offering of its common stock and issued 1,868,750 shares of common stock, including 243,750 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares.  The Company received cash proceeds of approximately $147.1 million, net of underwriting discounts and commissions and offering costs paid by the Company.

Data imported from Nevro Corp SEC filings. Check original filings before making any investment decision.